← Back to patent-cliff list
Nicotinamide riboside/Pterostilbene
Tier C — Watch / tradeNicotinamide riboside/Pterostilbene
Elysium Health
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：NAD(Nicotinamide adenine dinucleotide), SIRT5
Brand：Basis
Indications (approved)：急性肾损伤
Regional status
US
Phase II
2020-12-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nicotinamide riboside/Pterostilbene?
Approved indications include: 急性肾损伤.
When does the Nicotinamide riboside/Pterostilbene patent expire?
No public expiry year is available for Nicotinamide riboside/Pterostilbene yet; this page updates once verified.
How do I get a quote for Nicotinamide riboside/Pterostilbene intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06